UK markets closed

CVAC Jan 2023 130.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.10000.0000 (0.00%)
As of 01:28PM EDT. Market open.
Full screen
Previous close0.1000
Open0.1000
Bid0.0000
Ask0.5000
Strike130.00
Expiry date2023-01-20
Day's range0.1000 - 0.1000
Contract rangeN/A
Volume5
Open interest88
  • The Telegraph

    German drugmaker accused of stealing Covid vaccine technology

    The team behind Britain’s most-used Covid booster vaccine is being sued by a German pharmaceutical firm which has accused it of stealing the technology behind the jab.

  • Reuters

    CureVac files patent lawsuit in Germany against BioNTech over mRNA technology

    BERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking "fair compensation" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday. When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.

  • EQS Group

    CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

    Issuer: CureVac / Key word(s): Legal Matter05.07.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech TÜBINGEN, Germany/ Boston, USA – July 5, 2022 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that it has moved to assert its intellectual property rights, accumulated